Key StatisticsCurrency:USD
EPS(TTM)
-1.52
P/E(TTM)
-1.41
BVPS
3.06
P/B
0.69
Revenue(2024 Q4)
5.18M
YoY
58.75%
Net Income(2024 Q4)
-34.57M
YoY
0.52%
Gross Margin(TTM)
100.00%
Net Margin(TTM)
-295.96%
ROE(TTM)
-45.58%
Debt ratio
38.22%
Dividend Yield(TTM)
--
Payout Ratio
--
Unveiling the company's Dividend Strategy
Profile

C4 Therapeutics, Inc.
A developer of novel therapies for cancer and other diseases using its proprietary Cell Selection and Engineering (CSE) platform
Related Sections
- Biotechnology+1.37%
Pharma Tracker
No Upcoming Event
Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company
Revenue BreakdownCurrency:USD
Business
Region
Data source:2024 FY
Total
35.58M
Name
Revenue
Proportion
MKDG Agreement
7.30M
20.53%
MERCK Agreement
3.98M
11.18%
Betta Agreements
3.42M
9.60%
Roche Agreement
3.99M
11.21%
Biogen License Agreement
16.90M
47.49%
Major shareholders
Marc A. Cohen;Alain J. Cohen
Perceptive Advisors
Bihua Chen
DividendsCurrency:USD
No Data
Net Income Attributable to Parent
Total Cash Dividends
Payout Ratio
Unveiling the company's Dividend Strategy
Institutional Holdings
Totally
108
institutions reported their ownerships on CCCC
Institutional Holding Ratio
Price
Insider Transactions
Net increase
Net decrease
Price
Stock split and consolidation
Executive Profile
Executives
Board
Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.
Market Data Risk Disclosure|Privacy Policy